NICE Single Technology Appraisal Guidance No 189 – Sorafenib
for the treatment of advanced hepatocellular carcinoma
NICE Single Technology Appraisal Guidance No
189 – Sorafenib for the treatment of advanced
hepatocellular carcinoma
This NICE guidance was published on 26 May 2010.
The web reference for the appraisal and other related documents is:
http://www.nice.org.uk/TA189
NHSScotland should note that:
1. Recommendations of NICE Single Technology
Appraisals (STAs) have no status in NHSScotland.
2. NHS boards should adhere to the Scottish
Medicines Consortium (SMC) advice.
SMC published a Statement of Advice (482/08) on
this medication for this indication in January 2011. This
stated:
Sorafenib (Nexavar®) is not
recommended for use within NHSScotland for the treatment of
hepatocellular carcinoma.
Access the advice of SMC:
3. There is no material difference between the
recommendations of the NICE STA and SMC.
Published Date: 26 May 2010
